COVID-19. COVID_19
Conditions
Interventions
Intervention 1: Intervention group: The intervention group will receive 8 mg bromhexine tablets every 8 hours for 14 days. Intervention 2: Control group: They will receive 3 placebo tablets a day for
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 18 Years to 80 years old Both genders Having household contact or contact in less than 1.5 meters for more than one hour, or exposed without facemask with a COVID-19 case confirmed with RT-PCR or with clinical or radiographic evidence of pneumonia, acute respiratory distress syndrome (ARDS) Free of the COVID-19 disease symptoms (fever, cough, dyspnea, difficulty breathing, sore throat, severe fatigue, headache, GI symptoms) Free from chronic respiratory or other illnesses with symptoms confused with symptoms of COVID-19 disease Signed consent form
Exclusion criteria
Exclusion criteria: Less than 18 years Severe renal failure Severe liver disease Pregnant or breastfeeding woman or with a positive pregnancy test result Subjects on immune-modulating drugs for other diseases subjects on other clinical trials for COVID-19 within 30 days before or after randomization Subjects in other drug clinical trial Having an allergy to bromhexine hydrochloride or its ingredients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Test for the presence or absence of corona virus nucleic acid. Timepoint: 15 days after the intervention. Method of measurement: Real-time PCR.;Serum levels of IgM and IgG. Timepoint: 15 days after the intervention. Method of measurement: Immunological test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Khalil Ansarin
Tabriz University of Medical Sciences
Outcome results
None listed